GeneOne Life Science Inc Working Capital to Net Assets Ratio
GeneOne Life Science Inc working capital to net assets ratio. GeneOne Life Science Inc (011000) has a Working Capital to Net Assets ratio of -57.2% as of March 2026. Working capital of ₩-29.25 Billion (current assets of ₩24.67 Billion minus current liabilities of ₩53.92 Billion) is measured against net assets of ₩51.15 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check how tangible is GeneOne Life Science Inc's equity to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of GeneOne Life Science Inc (2013–2025)
Working capital to net assets ratio of GeneOne Life Science Inc from 2013 to 2025. This chart shows how GeneOne Life Science Inc's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at -57.2%, reflecting working capital of ₩-29.25 Billion against net assets of ₩51.15 Billion KRW. See 011000 days of operational coverage to measure how many days the company can operate on defensive assets alone.
GeneOne Life Science Inc Working Capital to Net Assets Ratio by Year (2013–2025)
GeneOne Life Science Inc working capital to net assets ratio by year from 2013 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for GeneOne Life Science Inc from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 011000 total asset value.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -84.0% | ₩-34.37 Billion | ₩40.90 Billion | ₩19.44 Billion | ₩53.81 Billion | ▼ -67.8 pp |
| 2024 | -16.2% | ₩-13.87 Billion | ₩85.61 Billion | ₩28.64 Billion | ₩42.51 Billion | ▼ -26.7 pp |
| 2023 | 10.5% | ₩11.71 Billion | ₩111.49 Billion | ₩34.57 Billion | ₩22.87 Billion | ▼ -11.1 pp |
| 2022 | 21.6% | ₩39.23 Billion | ₩181.47 Billion | ₩73.06 Billion | ₩33.84 Billion | ▼ -27.0 pp |
| 2021 | 48.6% | ₩99.87 Billion | ₩205.45 Billion | ₩134.63 Billion | ₩34.76 Billion | ▼ -24.5 pp |
| 2020 | 73.1% | ₩72.06 Billion | ₩98.51 Billion | ₩108.76 Billion | ₩36.71 Billion | ▲ +15.2 pp |
| 2019 | 58.0% | ₩13.94 Billion | ₩24.06 Billion | ₩36.60 Billion | ₩22.65 Billion | ▼ -7.9 pp |
| 2018 | 65.9% | ₩19.37 Billion | ₩29.41 Billion | ₩38.18 Billion | ₩18.81 Billion | ▼ -5.5 pp |
| 2017 | 71.4% | ₩26.08 Billion | ₩36.54 Billion | ₩34.65 Billion | ₩8.57 Billion | ▲ +3.8 pp |
| 2016 | 67.6% | ₩24.23 Billion | ₩35.85 Billion | ₩52.91 Billion | ₩28.68 Billion | ▼ -4.9 pp |
| 2015 | 72.5% | ₩28.59 Billion | ₩39.44 Billion | ₩35.28 Billion | ₩6.69 Billion | ▲ +0.0 pp |
| 2014 | 72.5% | ₩25.16 Billion | ₩34.73 Billion | ₩29.44 Billion | ₩4.28 Billion | ▲ +17.2 pp |
| 2013 | 55.2% | ₩13.09 Billion | ₩23.71 Billion | ₩19.50 Billion | ₩6.41 Billion | — |